To better understand the inconsistency of TRAIL-based therapies in osteosarcoma and Ewing sarcoma models, the objective of the present work was to explore the sensitivity of pediatric bone tumor cell lines and cell-derived xenograft models to TRAIL-based therapy, with a special emphasis on the induction of non-apoptotic pathways. This evidence concerns the gene TNFSF10 and bone neoplasm.